Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Recovering Zimbabwe Offers Growth Opportunities for Pharmaceutical Companies States Frost & Sullivan - Recovery from a decade-long economic contraction has been the main factor behind the growth experienced in Zimbabwe's pharmaceutical sector in the last two years
Recovering Zimbabwe Offers Growth Opportunities for Pharmaceutical Companies States Frost & Sullivan

 

PRZOOM - /newswire/ - Cape Town, South Africa, 2010/12/09 - Recovery from a decade-long economic contraction has been the main factor behind the growth experienced in Zimbabwe's pharmaceutical sector in the last two years.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A new coalition government and subsequent macro-economic stabilisation have brought renewed optimism and spurred demand in healthcare markets. This is driving the uptake of drugs – a trend that is expected to remain robust in the future with the increasing availability of low-cost generic drugs.

New analysis from Frost & Sullivan (medicaldevices.frost.com), Healthcare Overview in Zimbabwe, finds that the pharmaceutical market in Zimbabwe earned revenues of $200 million in 2009 and estimates this to reach $370.6 million in 2016.

“A recovering economy, which has brought price stability and rising incomes, is behind the increase in expenditure," notes Frost & Sullivan Healthcare Research Analyst Ishe Zingoni. “The increased availability of low-cost generic drugs, paralleled by the rising incidence of infectious diseases in the country, will boost pharmaceutical market development."

Zimbabwe is in the midst of economic recovery, and rising incomes are already driving the demand for quality healthcare products. Economic growth, coupled with the greater availability of affordable generic drugs, will spur the uptake of pharmaceuticals.

Over the course of Zimbabwe's economic slump, the country's once vibrant pharmaceutical industry had shrunk by over 50 per cent, and by 2008, capacity utilisation stood at a mere 20 per cent. Although the economy has since recovered, significant challenges remain for local manufacturers, mainly in the form of lack of capital.

“The country has struggled to attract capital and access loan facilities from international lenders due to the government's unfavourable credit record," explains Zingoni. “Limited access to capital has therefore inhibited investment in new plants and equipment, and thus production levels have remained low. Without an optimally operating manufacturing industry, shortages of affordable medicines will remain unresolved."

The direction of long-term policy in Zimbabwe and many countries in the sub-Saharan Africa is moving towards promoting local manufacturing of generic drugs. In that regard, foreign investors have an important role to play in the country's pharmaceutical sector.

As the economy of Zimbabwe has now stabilised, the opportunity for international investors lies in the provision of business capital, with possible guarantees negotiated with the government.

“Injection of capital into local firms would enable upgrade of facilities, and thus unlock new markets, most notably donor-financed tenders and regional export markets," concludes Zingoni. “A pre-requisite for suppliers wishing to tap into these markets is meeting WHO quality certification, standards which most local manufacturers currently do not meet."

Healthcare Overview in Zimbabwe is part of the Medical Devices Growth Partnership Services programme, which also includes research in the following markets: Strategic Analysis of Medical Imaging Devices in Kenya, Strategic Analysis of Medical Imaging devices In Ghana and Nigeria, Strategic Analysis of the Healthcare Industry in Kenya, Strategic Analysis of the Healthcare Industry in Tanzania and The Medical Insurance Markets in sub-Sahara Africa. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

If you are interested in more information about this study, please send an email to Christie Cronje, Corporate Communications, at christie.cronje[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.

Healthcare Overview in Zimbabwe / M5DC

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Recovering Zimbabwe Offers Growth Opportunities for Pharmaceutical Companies States Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Christie Cronje 
+27 18 464 2402 christie.cronje[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  RightITnow Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today